Waters Launches Bioseparation Columns to Accelerate GLP-1 and LNP Drug Development

Event summary

  • Waters Corporation launched BioResolve Peptide and GTxResolve Lipid Phenyl-Hexyl+ and C18+ Columns on June 8, 2026, designed for GLP-1 and lipid nanoparticle (LNP) analysis.
  • The columns offer up to 3x faster GLP-1 characterization and 2x faster LNP component analysis, addressing a persistent biopharmaceutical challenge.
  • The products are the first QC batch-tested specifically for GLP-1 analysis and lipid nanoparticles, solving a longstanding customer pain point.
  • BioResolve Peptide Columns resolve chemically similar GLP-1 impurities, while GTxResolve Lipid Columns improve peak shape and resolve challenging co-elutions in LNP workflows.

The big picture

Waters' new columns address critical bottlenecks in biopharmaceutical development, particularly for GLP-1 receptor agonists and mRNA-based therapies. The launch underscores the growing demand for advanced analytical technologies that can handle the complexity of modern biologics, ensuring faster, more reliable impurity resolution. This innovation is likely to influence the broader biopharmaceutical industry, where regulatory readiness and patient safety are paramount.

What we're watching

Adoption Pace
How quickly biopharmaceutical companies will integrate the new columns into their workflows, given the potential for faster and more accurate impurity analysis.
Regulatory Impact
Whether the improved resolution and speed of the columns will enhance regulatory confidence and accelerate drug approvals.
Competitive Response
How competitors in the bioseparation column market will react to Waters' innovation, particularly in addressing GLP-1 and LNP analysis challenges.